IL260923B - History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors - Google Patents
History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitorsInfo
- Publication number
- IL260923B IL260923B IL260923A IL26092318A IL260923B IL 260923 B IL260923 B IL 260923B IL 260923 A IL260923 A IL 260923A IL 26092318 A IL26092318 A IL 26092318A IL 260923 B IL260923 B IL 260923B
- Authority
- IL
- Israel
- Prior art keywords
- jak
- pyrazin
- pyrazolo
- inhibitors
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299130P | 2016-02-24 | 2016-02-24 | |
| PCT/IB2017/050748 WO2017144995A1 (fr) | 2016-02-24 | 2017-02-10 | Dérivés pyrazolo[1,5-a]pyrazin-4-yle comme inhibiteurs jac |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL260923B true IL260923B (en) | 2022-01-01 |
Family
ID=58054385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL260923A IL260923B (en) | 2016-02-24 | 2018-08-01 | History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors |
Country Status (45)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3419978T3 (da) | 2016-02-24 | 2020-06-02 | Pfizer | Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere |
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| WO2019178079A1 (fr) * | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibiteurs de la signalisation à médiation par la tyrosine kinase 2 |
| EP3793559A1 (fr) | 2018-05-17 | 2021-03-24 | Bayer Aktiengesellschaft | Dérivés de dihydropyrazolo pyrazine carboxamide substitués |
| CA3100731A1 (fr) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Derives de pyrimidine fusionnes utilises en tant qu'inhibiteurs de a2a/a2b |
| WO2020010197A1 (fr) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b |
| TW202033198A (zh) | 2018-10-17 | 2020-09-16 | 美商美國禮來大藥廠 | 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| AU2020256720B2 (en) * | 2019-04-12 | 2022-09-01 | PrimeGene (Beijing) Co. Ltd. | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof |
| SG11202112043PA (en) | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| WO2021048736A1 (fr) | 2019-09-11 | 2021-03-18 | Pfizer Inc. | Traitement de l'hidradénite avec des inhibiteurs de jak |
| TW202135816A (zh) * | 2019-12-18 | 2021-10-01 | 美商輝瑞股份有限公司 | 以激酶抑制劑治療潰瘍性結腸炎 |
| AU2021248720A1 (en) | 2020-04-04 | 2022-11-03 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| CA3179566A1 (fr) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Formes cristallines de 3-cyano-1-[4-[6-(1-methyl-1h-pyrazo-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, et utilisation associee |
| CN116568299A (zh) * | 2020-09-11 | 2023-08-08 | 普尔莫西姆治疗有限责任公司 | 用于治疗或预防肺动脉高压的组合物和方法 |
| CN112592345A (zh) * | 2020-12-07 | 2021-04-02 | 嘉兴特科罗生物科技有限公司 | 一种三氮唑并吡嗪类化合物及其用途 |
| WO2022165530A1 (fr) * | 2021-02-01 | 2022-08-04 | Janssen Biotech, Inc. | Inhibiteurs à petites molécules de kinases inductibles par le sel |
| US20240156822A1 (en) | 2021-03-30 | 2024-05-16 | Pfizer Inc. | Methods For Treatment of Vitiligo |
| CA3236262A1 (fr) | 2021-10-25 | 2023-05-04 | Isaac Marx | Agents de degradation de tyk2 et leurs utilisations |
| IL312782A (en) * | 2021-11-12 | 2024-07-01 | Soter Biopharma Pte Ltd | Pyrizolo's fused ring compound and its use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| AR066879A1 (es) * | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| HUE028347T2 (en) | 2008-06-10 | 2016-12-28 | Abbvie Inc | Tricyclic compounds |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| WO2010117787A2 (fr) | 2009-03-30 | 2010-10-14 | The Brigham And Women's Hospital, Inc. | Inhibition de l'enzyme ephb3 kinase |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| RU2012148246A (ru) * | 2010-04-14 | 2014-05-20 | Эррэй Биофарма Инк. | 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ |
| EP2397482A1 (fr) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK |
| CN103987713A (zh) | 2011-10-12 | 2014-08-13 | 阵列生物制药公司 | 5,7-取代的咪唑并[1,2-c]嘧啶 |
| US9187453B2 (en) * | 2012-03-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| PE20142186A1 (es) | 2012-03-28 | 2014-12-29 | Merck Patent Gmbh | Derivados biciclicos de pirazinona |
| MX2016001427A (es) | 2013-07-31 | 2016-08-03 | Gilead Sciences Inc | Inhibidores de syk. |
| TW201605811A (zh) | 2013-12-11 | 2016-02-16 | 阿爾米雷爾有限公司 | 作為jak抑制劑之吡唑并嘧啶-2基衍生物 |
| EP3137454A1 (fr) * | 2014-04-28 | 2017-03-08 | Pfizer Inc. | Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1 |
| WO2016009028A1 (fr) | 2014-07-17 | 2016-01-21 | Valeo Systèmes d'Essuyage | Balai plat caréné d'essuie-glace |
| HUE054371T2 (hu) * | 2014-12-05 | 2021-09-28 | Array Biopharma Inc | 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok |
| WO2016119707A1 (fr) | 2015-01-29 | 2016-08-04 | Hutchison Medipharma Limited | Nouveaux composés hétéroaryliques et hétérocycliques, compositions et procédés |
| CN113563342A (zh) | 2015-02-13 | 2021-10-29 | 达纳－法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
| GB201504565D0 (en) | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| EP3290418B1 (fr) | 2015-04-29 | 2019-05-15 | Wuxi Fortune Pharmaceutical Co., Ltd | Inhibiteurs de janus kinase (jak) |
| WO2017108723A2 (fr) | 2015-12-22 | 2017-06-29 | F. Hoffmann-La Roche Ag | Dérivés pyrazolo [1,5 a]pyrimidine en tant que modulateurs d'irak 4 |
| DK3419978T3 (da) | 2016-02-24 | 2020-06-02 | Pfizer | Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere |
| AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
| CN110785418A (zh) | 2017-06-21 | 2020-02-11 | 豪夫迈·罗氏有限公司 | 作为irak4调节剂的异二氢吲哚酮衍生物 |
| WO2019034973A1 (fr) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl et dérivés associés |
-
2017
- 2017-02-10 DK DK17705705.6T patent/DK3419978T3/da active
- 2017-02-10 MA MA052987A patent/MA52987A/fr unknown
- 2017-02-10 RS RS20200584A patent/RS60261B1/sr unknown
- 2017-02-10 PT PT177057056T patent/PT3419978T/pt unknown
- 2017-02-10 NZ NZ744349A patent/NZ744349A/en unknown
- 2017-02-10 MD MDE20190031T patent/MD3419978T2/ro unknown
- 2017-02-10 MY MYPI2018702937A patent/MY189118A/en unknown
- 2017-02-10 CU CU2018000078A patent/CU24511B1/es unknown
- 2017-02-10 TN TNP/2018/000295A patent/TN2018000295A1/en unknown
- 2017-02-10 EA EA201891463A patent/EA035036B1/ru unknown
- 2017-02-10 MX MX2018010236A patent/MX2018010236A/es unknown
- 2017-02-10 SI SI201730289T patent/SI3419978T1/sl unknown
- 2017-02-10 KR KR1020187024431A patent/KR102128671B1/ko active IP Right Grant
- 2017-02-10 JP JP2018544300A patent/JP6505956B2/ja active Active
- 2017-02-10 UA UAA201808148A patent/UA119835C2/uk unknown
- 2017-02-10 AU AU2017222417A patent/AU2017222417B2/en active Active
- 2017-02-10 CN CN201780013165.4A patent/CN109071546B/zh active Active
- 2017-02-10 CR CR20180372A patent/CR20180372A/es unknown
- 2017-02-10 GE GEAP201714864A patent/GEP20217242B/en unknown
- 2017-02-10 ES ES17705705T patent/ES2794779T3/es active Active
- 2017-02-10 WO PCT/IB2017/050748 patent/WO2017144995A1/fr active Application Filing
- 2017-02-10 EP EP20168877.7A patent/EP3712153B1/fr active Active
- 2017-02-10 SG SG11201806307YA patent/SG11201806307YA/en unknown
- 2017-02-10 LT LTEP17705705.6T patent/LT3419978T/lt unknown
- 2017-02-10 EP EP17705705.6A patent/EP3419978B1/fr active Active
- 2017-02-10 HU HUE17705705A patent/HUE049305T2/hu unknown
- 2017-02-10 ME MEP-2020-97A patent/ME03743B/fr unknown
- 2017-02-10 PL PL17705705T patent/PL3419978T3/pl unknown
- 2017-02-10 MA MA43668A patent/MA43668B1/fr unknown
- 2017-02-10 CO CONC2018/0008799A patent/CO2018008799A2/es unknown
- 2017-02-10 RU RU2018130547A patent/RU2718902C2/ru active
- 2017-02-21 TW TW106105777A patent/TWI665201B/zh active
- 2017-02-21 US US15/437,618 patent/US10144738B2/en active Active
- 2017-02-21 CA CA2958490A patent/CA2958490C/fr active Active
- 2017-02-22 UY UY0001037133A patent/UY37133A/es unknown
- 2017-02-23 AR ARP170100462A patent/AR107714A1/es unknown
-
2018
- 2018-07-18 SV SV2018005726A patent/SV2018005726A/es unknown
- 2018-07-24 ZA ZA2018/04972A patent/ZA201804972B/en unknown
- 2018-08-01 IL IL260923A patent/IL260923B/en unknown
- 2018-08-03 NI NI201800080A patent/NI201800080A/es unknown
- 2018-08-17 CL CL2018002358A patent/CL2018002358A1/es unknown
- 2018-08-23 PH PH12018501788A patent/PH12018501788A1/en unknown
- 2018-08-24 DO DO2018000187A patent/DOP2018000187A/es unknown
- 2018-09-24 EC ECSENADI201872109A patent/ECSP18072109A/es unknown
- 2018-11-06 US US16/181,596 patent/US10822341B2/en active Active
-
2019
- 2019-01-14 HK HK19100512.8A patent/HK1258157A1/zh unknown
-
2020
- 2020-05-13 HR HRP20200781TT patent/HRP20200781T1/hr unknown
- 2020-05-15 CY CY20201100470T patent/CY1122949T1/el unknown
- 2020-09-08 US US17/014,533 patent/US11472809B2/en active Active
-
2022
- 2022-09-07 US US17/939,375 patent/US20230045252A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物 | |
| HRP20211261T8 (hr) | [1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola | |
| ZA201905456B (en) | Pyrrolo[1,2-b]pyridazine derivatives | |
| HK1256751A1 (zh) | [1，2，4]三唑並[1，5-a]嘧啶-7-基化合物 | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| EP3280715A4 (fr) | Nouvelles imidazo[1,5-a]pyridines substituées en 5ème ou 8ème position en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| ZA201902562B (en) | Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides | |
| HK1254809A1 (zh) | 治療中有用的吡唑並[1，5-a]三嗪-4-胺衍生物 | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
| IL290419B (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors | |
| HK1257427A1 (zh) | 用於製備2-吡唑並[1，5-a]吡嗪-2-基吡啶並[1，2-a]嘧啶-4-酮的方法 |